EP Patent

EP2044929A1 — Oral fast distintegrating tablets

Assigned to Esteve Pharmaceuticals SA · Expires 2009-04-08 · 17y expired

What this patent protects

The present invention refers to an orally fast disintegrable pharmaceutically acceptable multiple units tablet dosage form comprising a) tablet excipients comprising a disintegrant and b) individual units wherein each individual unit comprises: i) a core material comprising at l…

USPTO Abstract

The present invention refers to an orally fast disintegrable pharmaceutically acceptable multiple units tablet dosage form comprising a) tablet excipients comprising a disintegrant and b) individual units wherein each individual unit comprises: i) a core material comprising at least one physiologically active substance; ii) a controlled release coating layer; and iii) an over-coating layer comprising a mixture of plasticizer agents.

Drugs covered by this patent

Patent Metadata

Patent number
EP2044929A1
Jurisdiction
EP
Classification
—
Expires
2009-04-08
Drug substance claim
No
Drug product claim
No
Assignee
Esteve Pharmaceuticals SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.